Open clinical study of antihypertensive efficacy of generic drug telmisartan (hypotel) or a combination with S-amlodipine (Semlopin) or hydrochlorothiazide in the therapy of patients with mild to moderate arterial hypertension (ah) (results of the hipster

Yu.M. Sirenko, O.L. Rekovets, E.P. Svischenko, L.M. Ena, E.A. Torbas, S.M. Kushnir, O.V. Gulkevych, I.V. Mudruk

Abstract


The aim of the study was to evaluate the antihypertensive effect of a generic drug telmisartan (Hypotel manufactured by Kusum Pharm, Ukraine) in monotherapy or in combination with S-amlodipine (Semlopin manufactured by Kusum Pharm, Ukraine) in patients with mild to moderate arterial hypertension. Materials and methods. The study included 40 patients with mild to moderate hypertension. After a seven-day wash-out period, all patients underwent initial examination and distribution into the groups by sealed-envelope method, depending on the prescribed antihypertensive therapy. At the end of the withdrawal period, criteria for inclusion in the study were evaluated again. If patients met inclusion criteria and had no exclusion criteria, they were randomized. Hypotel has been administered at a dose of 40–80 mg once daily for 2 weeks. In failure to reach target blood pressure less than 140/90 mmHg, Semlopin 2.5–5 mg once a day was added for 1 more month. If target blood pressure was not achieved, hydrochlorothiazide 12.5 mg once daily was added. Duration of follow-up was 6 months. Results. The average age of patients was 55.85 ± 2.09 years. The average weight was 87.30 ± 2.77 kg. Average body mass index — 29.41 ± 0.63 kg/m2. Average office systolic (SBP) and diastolic blood pressure (DBP) at baseline were 155.88 ± 1.63 mmHg and 92.60 ± 1.43 mmHg, respectively. The average heart rate (HR) — 71.40 ± 1.29 bpm. Mean blood pressure du­ring ambulatory monitoring was 139.37 ± 1.49 mmHg for SBP, 82.47 ± 1.84 mmHg — for DBP. Average daily HR — 71.38 ± 1.32 bpm. Against the background of Hypotel therapy, a reduction of office blood pressure in the whole group at the stages of 14 days, 4, 8 and 24 weeks was –14.0/7.7; –22.0/10.7; –25.5/13.5; –26.8/12.3 mmHg, respectively (p < 0.05) for all values. Lowering blood pressure during daily monitoring in patients receiving Hypotel, after 24 weeks of treatment was 15.7/9.3 mmHg for the entire period, for the day period — 15.3/9.2 mmHg, for the night period — 15.4/8.7 mmHg (p < 0.05) for all values. Reaching the target blood pressure during the office monitoring was 80 % for the whole group; in Hypotel monotherapy, 100 % of patients achieved the target blood pressure, in the combination therapy with Hypotel plus Semlopin — 72 % of patients. During the daily monito­ring, achievement of target BP in the whole group was 90 %, with Hypotel monotherapy — 93 %, and in combination of Hypotel with Semlopin — 80 %. The incidence of adverse reactions was 2.5 %. Conclusions. Telmisartan in monotherapy or in combination with S-amlodipine effectively lowers blood pressure during both the office measurement, and the daily monitoring for 24 weeks of treatment in patients with mild to moderate arterial hypertension.

Keywords


arterial hypertension; telmisartan; S-amlodipine; ambulatory blood pressure monitoring

References


Свіщенко Є.П., Міщенко Л.А., Мхітарян Л.С. та ін. Метаболічні та органопротекторні властивості телмісартану в пацієнтів із гіпертонічною хворобою // Артеріальна гіпертензія. — 2014. — № 6. — С. 33-38.

Селюк М.Н. Телмисартан в лечении артериальной гипертензии: мы можем позволить себе лучшее // Здоров’я України. — 2016. — № 5. — С. 45.

Сиренко Ю.Н., Рековец О.Л. Антигипертензивная эффективность и безопасность телмисартана (микардиса) при артериальной гипертензии: первые результаты проспективного многоцентрового исследования в Украине // Український кардіологічний журнал. — 2003. — № 5. — С. 43-50.

Сіренко Ю.М., Рековець О.Л. Лікування артеріальної гіпертензії та метаболічних порушень: значення подвійного ефекту телмісартану для профілактики розвитку цукрового діабету // Ліки України. — 2005. — № 4. — С. 1-7.

Aranda P., Ruilope L.M., Calvo C. et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study // Am. J. Hypertens. — 2004. — Vol. 17(2). — P. 139-145.

Barnett A.H. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study // Acta Diabetol. — 2005. — Vol. 42, ­Suppl. 1. — S42-49.

Böger R.H., Schwedhelm E., Maas R., Quispe-Bravo S., Skamira C. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VI­VALDI study // Vasc. Med. — 2005. — Vol. 10, ­Suppl. 1. — S. 97-102.

Delles C., Raff U., Mimran A. еt al. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes (TRENDY) // Am. J. Hypertens. — 2008. — Vol. 21(12). — P. 1330-1336.

Doumas M., Tsakiris A., Douma S. et al. Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects // J. Androl. — 2006. — Vol. 27(3). — P. 469-477.

Galle J., Schwedhelm E., Pinnetti S., Böger R.H., Wanner C.; VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy // Nephrol. Dial Transplant. — 2008 — Vol. 23(10) — P. 3174-3183.

Gosse P., Schumacher H. Effect of telmisartan vs. ramipril on dipping status and blood pressure variability: pooled analysis of the PRISMA studies // Hypertens. Res. — 2014. — Vol. 37(2). — P. 151-157.

Greenstein A., Chen J., Miller H. et al. Does severity of ischemic coronary disease correlate with erectile function? // Int. J. Impot. Res. — 1997. — Vol. 9(3). — P. 123-126.

Kintscher U., Lyon C.J., Law R.E. Angiotensin II, PPAR-gamma and atherosclerosis // Front. Biosci. — 2004. — Vol. 1. — P. 359-369.

Kota B.P., Huang T.H., Roufogalis B.D. An overview on biological mechanisms of PPARs // Pharmacol. Res. — 2005. — Vol. 51. — P. 85-94.

Makino H., Haneda M., Babazono T. еt al. INNOVATION Study Group. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study // Hypertens. Res. — 2008 — Vol. 31(4). — P. 657-664.

Manolis A.J., Reid J.L., de Zeeuw D., Murphy M.B., Seewaldt-Becker E., Köster J.; ARAMIS Study Group. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo // J. Hypertens. — 2004. — Vol. 22(5). — P. 1033-1037.

Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardio­logy // J. Hypertension. — 2007. — Vol. 25. — P. 1105-1187.

Mancia G., Laurent S., Agabiti-Rosei E. et al. Reapparaisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. — 2009. — Vol. 27. — P. 2121-2158.

Ogawa H., Soejima H., Matsui K. еt al.; ATTEMPT-CVD investigators. A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study // Eur. J. Prev. Cardiol. — 2016 — Vol. 23(9) — P. 913-921

Peng G.C., Wang Y.F., Xiao Y. еt al. Blood pressure lo­wering efficacy of telmisartan and amlodipine taking on the mor­ning or at bedtime: ABPM results // Zhonghua Xin Xue Guan Bing Za Zhi. — 2013 — Vol. 41(6) — P. 484-487.

Raji A., Seely E.W., Bekins S.A. et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients // Diabetes Care. — 2003. — Vol. 26. — Р. 172-178.

Schiffrin E.L., Amiri F., Benkirane K., Iglarz M., Diep Q.N. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension // Hypertension. — 2003. — Vol. 42. — P. 664-668.

Schmieder R.E. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? (TRENDY) // J. Hypertens. Suppl. — 2006. — Vol. 24(2). — S31-35.

Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity // Circulation. — 2004. — Vol. 4. — P. 2054-2057.

Yamagishi S., Takeuchi M. Telmisartan is a promi­sing cardiometabolic sartan due to its unique PPAR-gamma-inducing property // Med. Hypotheses. — 2005. — Vol. 64. — P. 476-478.

Park C.G., Ahn T.H., Cho E.J. еt al. Comparison of the Efficacy and Safety of Fixed-dose S-Amlodipine/Telmisartan and Telmisartan in Hypertensive Patients Inadequately Controlled with Telmisartan: A Randomized, Double-blind, Multicenter Study // Clin. Ther. — 2016. — Vol. 38(10). — P. 2185-2194.

Ihm S.H., Jeon H.K., Cha T.J. еt al. Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monothe­rapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study // Drug Des. Devel. Ther. — 2016. — Vol. 10. — Р. 3817-3826.




DOI: https://doi.org/10.22141/2224-1485.1.51.2017.96247

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru